Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

Please visit answersincme.com/PYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses TROP2-directed antibody-drug conjugates (ADCs) for the treatment of patients with advanced, pretreated EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced, pretreated EGFR-mutated NSCLC; Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced, pretreated EGFR-mutated NSCLC; and Outline evidence-based strategies to incorporate TROP2-directed ADCs for patients with advanced, pretreated EGFR-mutated NSCLC.

There are no comments yet.

Please log in to write the first comment.